AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01942915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cells
Description: Participants will be transplanted with umbilical cord blood mononuclear cells.
Study NCT02265120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
Study NCT04348669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
Study NCT03138499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03138499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Specified dose on specified days
Study NCT03836651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)
Description: Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
Study NCT03836651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
Study NCT00002494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00002494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00002494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study NCT00002494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002494 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002494 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT01520675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: Drainage procedure
Study NCT03415698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
Study NCT03415698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
Study NCT01520675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: pancreatic sphincterotomy, removal of calculi, stenting, ESWL
Study NCT01017289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum
Description: Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
Study NCT03963076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)
Description: One spray of nasal hypertonic spray morning and evening every day during 30 days
Study NCT02842255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrate the oximeter ALTITRAINER200®
Description: During normoxic condition and four situations of hypoxia.
Study NCT03745352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT02981173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.143 mg/kg Psilocybin or 10 mg Psilocybin
Description: 0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
Study NCT02981173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.0143 mg/kg Psilocybin or 1 mg Psilocybin
Description: 0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
Study NCT02981173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
Study NCT03745352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Given IV or SC
Study NCT03745352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study NCT01034371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct coronary artery bypass
Description: MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
Study NCT01034371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI-Drug eluting stents
Description: PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES).
Study NCT01034371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-pump coronary artery bypass
Description: Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
Study NCT02523742 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IMRf
Study NCT00513071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study NCT00513071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00619346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, BID X 14 days
Study NCT00619346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pafuramidine maleate
Description: Pafuramidine maleate, 100 mg tablet BID X 14 days
Study NCT02523742 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: language task and a reference task (rest and Tamil)
Study NCT03918213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-Resolution anorectal manometry with the use of solid-state catheter
Description: High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
Study NCT02790632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-1962 (nimodipine microparticles)
Description: Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
Study NCT03016832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drug that simulates Irbesartan tablets
Description: Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
Study NCT03016832 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: irbesartan tablets
Description: irbesartan tablets 150mg /qd, oral dosing
Study NCT03016832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan tablets
Description: irbesartan tablets 150mg /qd, oral dosing
Study NCT03016832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drug that simulates HuangKui capsule
Description: Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
Study NCT03016832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuangKui Capsule
Description: HuangKui Capsule 2.5g/tid, oral dosing.
Study NCT03016832 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HuangKui Capsule
Description: HuangKui Capsule 2.5g/tid, oral dosing.
Study NCT03087110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matched sibling donor cord blood cell infusion
Description: Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (>1x10\^7 cells/kg)
Study NCT02710110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerLung trainer
Description: PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
Study NCT02710110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PowerLung trainer
Description: PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
Study NCT02710110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro Mouth Pressure Meter
Description: The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
Study NCT02710110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Micro Mouth Pressure Meter
Description: The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
Study NCT02710110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing
Description: Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
Study NCT02710110 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulmonary Function Testing
Description: Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
Study NCT02710110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallowing study
Description: Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
Study NCT02710110 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Videofluoroscopic swallowing study
Description: Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
Study NCT02710110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing Quality of Life Questionnaire
Description: Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
Study NCT02710110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Swallowing Quality of Life Questionnaire
Description: Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
Study NCT03796143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Mindfulness and Acceptance Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study NCT03796143 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Mindfulness and Acceptance Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study NCT03796143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Cognitive Behavioral Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study NCT02710110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa Oral Pressure Instrument
Description: The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
Study NCT02710110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Iowa Oral Pressure Instrument
Description: The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
Study NCT02710110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
Study NCT02710110 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Capsaicin
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
Study NCT03137173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole medocaril
Description: ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
Study NCT03137173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin+aztreonam
Description: Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.
Study NCT01276873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal aspiration close system
Description: use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
Study NCT01509157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDRS System (Remote & Safety diabetes management system)
Description: Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
Study NCT01509157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
Study NCT02053597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
Study NCT02053597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
Study NCT02062099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment
Study NCT01304927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol and calcium
Description: Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
Study NCT01304927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose maltodextrin Arachidis oil
Study NCT03377166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bucket test and Smartphone-based evaluation of SVV
Description: Bucket test and Smartphone-based evaluation of SVV
Study NCT04335357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBR-760
Description: TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
Study NCT04335357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03608462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(DLPFC)
Description: high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
Study NCT03608462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(LPC)
Description: high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
Study NCT02653989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDV9300
Description: MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
Study NCT01854957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Single dose of 1-2 x 1000000 cells/Kg body weight
Study NCT03125902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Description: Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
Study NCT03125902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Placebo
Description: Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
Study NCT03796143 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Cognitive Behavioral Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study NCT03467984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVE
Description: Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
Study NCT03467984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: 13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
Study NCT01816906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Footwear :PU
Description: One group of patients will receive Footwear with PU insoles